Biologics’ Clinical Therapeutic Intelligence Office was established to advance the company’s clinical expertise efforts as it continues to distinguish itself as a leader in pharmacy services, specifically within the oncology sector.
Clinical Therapeutic Intelligence Report: Special Edition
Nine new orals have been approved in the oncology space in 2015 year to date, with seven new indications for previously approved therapiesi. The approvals span multiple indications, routes of administration and mechanisms of action, and include orphan and breakthrough therapies.
“The continued development of effective therapeutics based on our understanding of cancer biology and the ability through the use of biomarkers to personalize therapies have lead to further expand options for patients across multiple malignancies,” said Dr. Mark Socinski, Director, Lung Cancer Section, Division of Hematology/Oncology at the University of Pittsburgh.